Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT

JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

Corporate Highlights

First Half 2026 Financial Results

CEO Commentary

Amir Reichman, Chief Executive Officer of Scinai, commented:

"The first half of 2026 was focused on expanding and integrating our CDMO platform. As we move through the second half of the year, our focus is increasingly on commercial execution, increasing facility utilization and converting the capabilities we have built into revenue.

We are particularly encouraged by the expansion of an existing U.S. customer engagement from an initial feasibility and cGMP-readiness project into a broader proposed clinical manufacturing and CMC program designed to support a planned U.S. IND submission and Phase III clinical development with potential future expansion into commercial manufacturing. We have already received approximately $650 thousand in cash payments and advances and commenced substantive activities while the definitive agreement covering the expanded scope and commercial terms is being negotiated.

We believe this opportunity is significant not only because of its potential financial contribution, but also because successful execution would demonstrate our ability to support an advanced U.S. clinical development program through CMC development, manufacturing readiness and clinical cGMP manufacturing.

Our priorities for the remainder of 2026 are clear: execute our existing customer programs, convert our commercial pipeline into revenue, increase utilization of our Jerusalem and Yavne facilities, progress this significant U.S. opportunity and continue advancing our therapeutic programs with disciplined capital allocation."

R&D Update

Scinai continues to pursue a capital-efficient development strategy focused on PC111 and its NanoAbs platform.

For PC111, the Company is evaluating its funding and development path, including potential participation in a future Polish FENG funding round, and is in discussions with PinCell regarding a potential extension of the existing option arrangement.

For the NanoAbs platform, Scinai continues to prioritize its systemic IL-17 bispecific antibody program and its research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Investor Webinar

Scinai will provide additional perspective on the expanded U.S. clinical manufacturing opportunity, its broader CDMO commercial pipeline, progress across its R&D programs, including PC111 and the NanoAbs platform, and its strategic priorities for the remainder of 2026 during an investor webinar on August 26, 2026 at 11:00 a.m. EDT.

Investors and other interested parties are invited to register here: LINK

The webinar will include a management presentation followed by a question-and-answer session.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization.

The Company is advancing therapeutic programs based on technology licensed from the Max Planck Society and pursuant to its option arrangement with PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | [email protected]

Investor Relations, Allele Capital Partners | +1 978 857 5075 | [email protected]

(1) Committed Customer Orders

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the growth of the Company's CDMO business; Committed Customer Orders; future and expansion of existing customer engagements and business-development opportunities; utilization of the Jerusalem and Yavne facilities.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks that the Company will be unable to execute customer projects and convert commercial opportunities into recognized revenue and cash flow; that the contemplated expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company will not be an beneficial to the Company as anticipated, will not occur or will be delayed; that the Company will not successfully negotiate and execute definitive customer agreements; that the Company will not successfully perform development, scale-up and cGMP manufacturing activities; that the Company will not increase facility utilization, attract and retain customers and partners; that the Company will not achieve its revenue targets; that the Company will not successfully advance its PC111 and the NanoAbs platform; that the Company will not succeed in obtaining potential non-dilutive funding from its grant applications; that the Company will be unable to obtain sufficient financing or non-dilutive funding; and that the Company will be unable to regain and maintain compliance with Nasdaq's continued-listing requirements. Additional risks and uncertainties are described in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements.

SCINAI IMMUNOTHERAPEUTICS LTD

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

As of June 30, 2026

Unaudited

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

June 30,

December 31,

2026

2025

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

2,654

1,661

Restricted cash

199

150

Prepaid expenses and other receivables

561

170

Trade receivables

Total current assets

3,488

2,054

NON-CURRENT ASSETS:

Property, plant and equipment, net

10,711

7,793

Operating lease right-of-use assets

2,976

1,779

Total non-current assets

13,687

9,572

Total assets

17,175

11,626

The accompanying notes are an integral part of the condensed consolidated financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share data)

June 30,

December 31,

2026

2025

LIABILITIES NET OF CAPITAL DEFICIENCY

CURRENT LIABILITIES:

Trade payables

844

407

Operating lease liabilities

369

329

Other payables

1,019

849

Total current liabilities

2,232

1,585

NON-CURRENT LIABILITIES:

Loan from others

285

294

Non-current operating lease liabilities

2,926

1,644

Total non-current liabilities

3,211

1,938

CONTINGENT LIABILITIES AND COMMITMENTS

SHAREHOLDERS' EQUITY:

Ordinary shares of no par value: Authorized: 1,600,000,000,000

shares at June 30, 2026 and at December 31,

2025; Issued and outstanding 22,800,887,584, shares at

June 30, 2026 and 13,872,899,584 shares at December

31, 2025

Preferred shares, no par value; Authorized: 1,000 shares

at June 30, 2026 and 1,000 shares at December 31, 2025

(redemption amount of $34,000); Issued and outstanding:

1,000 shares at June 30, 2026 and 1,000 shares at

December 31, 2025.

5,627

Additional paid-in capital

132,516

130,062

Accumulated deficit

(124,272)

(125,846)

Accumulated other comprehensive loss

(2,139)

(1,740)

Total shareholders' equity

11,732

8,103

Total liabilities and shareholders' equity

17,175

11,626

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share data)

For the six months ended June 30,

2026

2025

Revenues

949

773

Cost of revenues

(3,319)

(2,043)

Gross profit (loss)

(2,370)

(1,270)

Research and development expenses, net

(839)

(1,237)

Marketing, general, and administrative expenses

(1,404)

(1,256)

Total operating expenses

(2,243)

(2,493)

Total operating profit (loss)

(4,613)

(3,763)

Gain from bargain purchase

6,401

Total Financial Income (Expenses) net,

(214)

(371)

Net profit (loss)

1,574

(4,134)

Net loss per share attributable to ordinary shareholders, basic

and diluted

(*)

(0.001)

Weighted average number of shares used in computing net

loss per share attributable to ordinary shareholders, basic

and diluted

30,189,667,540

6,364,731,650

*Less than $0.01

The accompanying notes are an integral part of the condensed consolidated financial statements.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share data)

For the six months ended June 30

2026

2025

Net profit (loss)

1,574

(4,134)

Other comprehensive income:

Foreign currency translation

adjustments

(399)

Total comprehensive profit (loss)

1,175

(4,134)

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

U.S. dollars in thousands (except share data)

Ordinary shares

Preferred shares

Additional

Accumulated

Total

Number

Amount

Number

Amount

paid-in capital

comprehensive loss

equity (deficit)

shareholders'

equity (deficit)

Balance as of January 1, 2026

13,872,899,584

1,000

5,627

130,062

(1,740)

(125,846)

8,103

Vested RSU's

279,100,000

Share-based compensation

128

Issuance of pre-funded warrants, net of

issuance costs

8,598,960,000

2,321

Cumulative translation adjustment

(399)

Issuance of ordinary shares

49,928,000

Net profit (loss)

1,574

Balance as of June 30, 2026

22,800,887,584

1,000

5,627

132,516

(2,139)

(124,272)

11,732

*Ordinary shares have no par value

Ordinary shares

Preferred shares

Additional

Accumulated

Total

Number

Amount

Number

Amount

paid-in capital

comprehensive loss

Accumulated

equity (deficit)

shareholders'

equity (deficit)

Balance as of January 1, 2025

3,411,983,584

1,000

5,627

123,629

(1, 740(

(

(117,539 )

9,977

Vested RSU's

32,816,000

Share-based compensation

270

Exercise of prefunded warrants

322,944,000

Issuance of ordinary shares

2,288,880,000

1,745

Net loss

(4,134)

Balance as of June 30, 2025

6,056,623,584

1,000

5,627

125,644

(1,740()

(121,673)

7,858

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

For the six months

ended June 30,

2026

2025

Cash flows from operating activities:

Net profit (loss)

1,574

(4,134)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

Depreciation of property, plant and equipment

1,039

704

Financial expense (income) related to loan from others

(9)

Share-based compensation

128

270

Decrease (increase) in trade receivables

129

(56)

Gain from bargain purchase

(6,401)

Decrease (increase) in other receivables

(233)

(23)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(226)

(42)

SEPA commitment fees

164

Changes in operating lease right-of-use assets

117

Increase in trade payables

264

283

Changes in operating lease liabilities

(117)

237

Increase (decrease) in other payables

(185)

(42)

Net cash used in operating activities

(3,920)

(2,575)

Cash flows from investing activities:

Purchase of property, plant and equipment

(115)

(12)

Cash received in business combination

2,751

Net cash used in investing activities

2,636

(12)

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

For the six months ended June 30,

2026

2025

Cash flows from financing activities:

Proceeds from issuance of ordinary shares for SEPA holders, net

1,581

Proceeds pre-funded warrants for PIPE holders, net

2,321

Net cash provided by financing activities

2,326

1,581

Effect of exchange rate changes on cash, cash equivalents and restricted cash

Increase (decrease) in cash, cash equivalents and restricted cash

1,042

(946)

Cash, cash equivalents and restricted cash at beginning of period

1,811

2,095

Cash, cash equivalents and restricted cash at end of period

2,853

1,131

Non-cash transactions:

Shares issued for SEPA financing agreement

100

Reconciliation of cash, cash equivalents and restricted cash:

Cash and cash equivalents

2,654

989

Restricted cash

199

142

Cash, cash equivalents and restricted cash

2,853

1,131

SOURCE Scinai Immunotherapeutics Ltd.